
	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands, except share and per share amounts)	2026		2025		2026		2025
Numerator:



Net loss attributable to common stockholders	$	(42,109)	$	(52,591)	$	(91,231)	$	(104,481)
Denominator:
Weighted-average common shares outstanding, basic and diluted	177,224,892		129,185,918		177,160,914		128,439,349
Net loss per share attributable to common stockholders, basic and diluted	$	(0.24)	$	(0.41)	$	(0.51)	$	(0.81)

Diluted net loss per share available to common stockholders is computed by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, outstanding time-based stock options to purchase common stock, vested performance-based stock options to purchase common stock, and

unvested performance-based restricted stock awards were considered common stock equivalents but had been excluded from the calculation of diluted net loss per share available to common stockholders as their effect was anti-dilutive. In periods in which the Company reports a net loss available to common stockholders, diluted net loss per share available to common stockholders is the same as basic net loss per share available to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.

The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:


	As of June 30,
	2026	2025
Anti-dilutive common stock equivalents:
Options to purchase common stock	22,547,914	17,685,319
Unvested performance-based restricted common stock awards	3,472,546	3,472,546
Total anti-dilutive common stock equivalents:	26,020,460	21,157,865